KOL Identification

A cancer diagnostics company wanted to understand the current and future landscape for RNA-based oncology biomarkers, focusing on gene expression profiling (GEP) and rearrangements across medical settings

A group asked DeciBio to identify and evaluate clinical genetic testing labs for potential acquisition

A leading diagnostics player asked DeciBio to characterize the evolving NIPT market to help inform strategic positioning regarding menu offerings and technological approach

The ventures arm of a top-20 U.S. health system sought support developing a go-to-market strategy for RWD-augmented biobank offerings

A leading diagnostics player wanted an assessment of the current and future carrier screening landscape, primarily in the U.S., to guide their product development strategy

A diagnostics company requested DeciBio to help an advisory board (ad board) to understand how to position its relatively new somatic oncology genomics profiling product in an already competitive market